237 related articles for article (PubMed ID: 38182059)
1. Nanotechnology for enhanced nose-to-brain drug delivery in treating neurological diseases.
Huang Q; Chen Y; Zhang W; Xia X; Li H; Qin M; Gao H
J Control Release; 2024 Feb; 366():519-534. PubMed ID: 38182059
[TBL] [Abstract][Full Text] [Related]
2. [Development of Noninvasive Drug Delivery Systems to the Brain for the Treatment of Brain/Central Nervous System Diseases].
Kanazawa T
Yakugaku Zasshi; 2018; 138(4):443-450. PubMed ID: 29607986
[TBL] [Abstract][Full Text] [Related]
3. A Patent Review on Nanotechnology-Based Nose-to-Brain Drug Delivery.
Singh R; Brumlik C; Vaidya M; Choudhury A
Recent Pat Nanotechnol; 2020; 14(3):174-192. PubMed ID: 32384043
[TBL] [Abstract][Full Text] [Related]
4. Drug delivery systems from nose to brain.
Misra A; Kher G
Curr Pharm Biotechnol; 2012 Sep; 13(12):2355-79. PubMed ID: 23016642
[TBL] [Abstract][Full Text] [Related]
5. The blood-brain barrier and nasal drug delivery to the central nervous system.
Miyake MM; Bleier BS
Am J Rhinol Allergy; 2015; 29(2):124-7. PubMed ID: 25785753
[TBL] [Abstract][Full Text] [Related]
6. Management of epileptic disorders using nanotechnology-based strategies for nose-to-brain drug delivery.
Shringarpure M; Gharat S; Momin M; Omri A
Expert Opin Drug Deliv; 2021 Feb; 18(2):169-185. PubMed ID: 32921169
[TBL] [Abstract][Full Text] [Related]
7. Recent patents review on intranasal administration for CNS drug delivery.
Jogani V; Jinturkar K; Vyas T; Misra A
Recent Pat Drug Deliv Formul; 2008; 2(1):25-40. PubMed ID: 19075895
[TBL] [Abstract][Full Text] [Related]
8. Insights into direct nose to brain delivery: current status and future perspective.
Mittal D; Ali A; Md S; Baboota S; Sahni JK; Ali J
Drug Deliv; 2014 Mar; 21(2):75-86. PubMed ID: 24102636
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology-mediated nose to brain drug delivery for Parkinson's disease: a mini review.
Kulkarni AD; Vanjari YH; Sancheti KH; Belgamwar VS; Surana SJ; Pardeshi CV
J Drug Target; 2015; 23(9):775-88. PubMed ID: 25758751
[TBL] [Abstract][Full Text] [Related]
10. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease.
Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC
Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421
[TBL] [Abstract][Full Text] [Related]
11. Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases.
Fan Y; Chen M; Zhang J; Maincent P; Xia X; Wu W
Crit Rev Ther Drug Carrier Syst; 2018; 35(5):433-467. PubMed ID: 30317945
[TBL] [Abstract][Full Text] [Related]
12. Navigating the Nose-to-Brain Route: A Systematic Review on Lipid-Based Nanocarriers for Central Nervous System Disorders.
Agosti E; Zeppieri M; Antonietti S; Battaglia L; Ius T; Gagliano C; Fontanella MM; Panciani PP
Pharmaceutics; 2024 Feb; 16(3):. PubMed ID: 38543223
[TBL] [Abstract][Full Text] [Related]
13. Lipid nanoparticles strategies to modify pharmacokinetics of central nervous system targeting drugs: Crossing or circumventing the blood-brain barrier (BBB) to manage neurological disorders.
Correia AC; Monteiro AR; Silva R; Moreira JN; Sousa Lobo JM; Silva AC
Adv Drug Deliv Rev; 2022 Oct; 189():114485. PubMed ID: 35970274
[TBL] [Abstract][Full Text] [Related]
14. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
15. Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy.
Khatri DK; Preeti K; Tonape S; Bhattacharjee S; Patel M; Shah S; Singh PK; Srivastava S; Gugulothu D; Vora L; Singh SB
Curr Neuropharmacol; 2023; 21(3):493-516. PubMed ID: 35524671
[TBL] [Abstract][Full Text] [Related]
16. Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting.
Sonvico F; Clementino A; Buttini F; Colombo G; Pescina S; Stanisçuaski Guterres S; Raffin Pohlmann A; Nicoli S
Pharmaceutics; 2018 Mar; 10(1):. PubMed ID: 29543755
[TBL] [Abstract][Full Text] [Related]
17. Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.
Bruinsmann FA; Richter Vaz G; de Cristo Soares Alves A; Aguirre T; Raffin Pohlmann A; Stanisçuaski Guterres S; Sonvico F
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779126
[TBL] [Abstract][Full Text] [Related]
18. Nose to brain transport pathways an overview: potential of nanostructured lipid carriers in nose to brain targeting.
Selvaraj K; Gowthamarajan K; Karri VVSR
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):2088-2095. PubMed ID: 29282995
[TBL] [Abstract][Full Text] [Related]
19. The uses of resveratrol for neurological diseases treatment and insights for nanotechnology based-drug delivery systems.
Fonseca-Santos B; Chorilli M
Int J Pharm; 2020 Nov; 589():119832. PubMed ID: 32877730
[TBL] [Abstract][Full Text] [Related]
20. Application of Therapeutic Nanoplatforms as a Potential Candidate for the Treatment of CNS Disorders: Challenges and Possibilities.
Sa P; Singh P; Dilnawaz F; Sahoo SK
Curr Pharm Des; 2022; 28(33):2742-2757. PubMed ID: 35909283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
